Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Incorporating Immune Checkpoint Inhibitors Into Practice for Advanced Urothelial Cancer: Expert Perspectives From the United States

In this episode, listen to Petros Grivas, MD, PhD, and Jonathan E. Rosenberg, MD, discuss key data on immune checkpoint inhibitors for urothelial carcinoma informing their clinical practice in the United States.
Petros Grivas, MD, PhD
Jonathan E. Rosenberg, MD
Released: February 1, 2021

In this episode, Petros Grivas, MD, PhD, and Jonathan E. Rosenberg, MD, discuss key data on immune checkpoint inhibitors for urothelial carcinoma informing their clinical practice in the United States. Topics include:

  • Guideline changes for first-line UC based on data from JAVELIN Bladder 100 trial on avelumab maintenance after chemotherapy
  • Results from IMvigor130 and KEYNOTE-361 trials on concurrent immune checkpoint inhibition plus chemotherapy
  • When to consider first-line treatment with immune checkpoint inhibitor monotherapy
  • Utility of PD-L1 as biomarker for immune checkpoint inhibitor–based therapy
  • Monitoring for and managing immune-related adverse events during the COVID-19 pandemic

Presenters:

Petros Grivas, MD, PhD
Associate Professor
Clinical Director, Genitourinary Cancers Program
Division of Medical Oncology
Department of Medicine
University of Washington
Seattle Cancer Care Alliance
Seattle, Washington, USA

Jonathan E. Rosenberg MD
Attending Physician
Chief, Genitourinary Oncology Service
Division of Solid Tumor Oncology
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York, USA

Acknowledgements

Supported by an educational grant from
Pfizer, Inc. and EMD Serono

Related Content

First results from PEACE-1 trial of abiraterone with or without local radiotherapy plus SOC in metastatic CSPC, from ASCO 2021 as reported by Clinical Care Options (CCO)

Released: June 17, 2021

Downloadable slideset from Eric Jonasch, MD on managing irAEs in patients with advanced RCC, from Clinical Care Options (CCO).

Eric Jonasch, MD Released: June 16, 2021

Downloadable slideset from Dr Elizabeth R. Plimack on first-line treatment options for patients with RCC, from Clinical Care Options (CCO)

Elizabeth R. Plimack, MD, MS Released: June 16, 2021

Downloadable slideset from Neeraj Agarwal, MD on treatment options for salvage therapy in advanced RCC, from Clinical Care Options (CCO)

Neeraj Agarwal, MD Released: June 16, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue